BioSpace News Archive

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced the publication of two manuscripts in The Lancet Oncology reporting long-term Phase I safety and preliminary efficacy results of trastuzumab deruxtecan (DS-8201).

PCI Pharma Services (PCI), full-service provider of specialist outsourced drug manufacturing, clinical trial services and commercial packaging to the global biopharmaceutical industry, will showcase its expertise in Phase I Clinical Trials in Australia with a series of East Coast, US seminars in June 2019.

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today will report new preclinical data demonstrating that ABO-401, the Company’s novel gene therapy for cystic fibrosis (CF), efficiently delivered a highly-expressed, functional copy of human mini-CFTR (hCFTR) to the lung of CF mice and restored CFTR function in human CF patient nasal and bronchial epithelial cells.

Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, today announced that data from five studies will be highlighted in two oral presentations and three poster sessions at the American Society of Gene & Cell Therapy 22nd Annual Meeting, taking place between 29 April and 2 May in Washington, DC, USA.

Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, notes that Axovant Gene Therapies Ltd. (NASDAQ: AXGT) has announced the dosing of the first patient of the second cohort in the SUNRISE-PD Phase 2 trial of AXO-Lenti-PD in Parkinson’s disease patients.

Hollywood turned out Monday night to honor couples Actor Zoe Saldana-Perego and Artist Marco Perego-Saldana and Paramount Pictures’ Wyck Godfrey and Dr. Mary Kerr for their support of quality health care for women and their families wherever they live—the global mission of Jhpiego, an affiliate of Johns Hopkins University.

Our annual 5K, Mother’s Day Walk will take place in 10 cities across Canada this May to raise money for breast cancer research.

Technology Minimizes Invasiveness of Certain Laparoscopic and Robotic Surgeries, Enabling Procedures with a Reduced Number of Incisions While Facilitating Surgical Access and Visualization

3-V Biosciences, Inc. and Ascletis Pharma Inc. announced that 3-V Biosciences has recently dosed its first patient in a Phase 2 clinical trial of the FASN inhibitor TVB-2640 in patients with non-alcoholic steatohepatitis.

Amgen announced financial results for the first quarter of 2019.